Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort
复制标题
DOI：
10.1016/j.jaad.2019.02.053
复制
发表时间：
2019-07-01
影响因子：
13.8
通讯作者：
Staumont-Salle, Delphine
中科院分区：
文献类型：
--
作者：
Faiz, Sarah;Giovannelli, Jonathan;Staumont-Salle, Delphine
背景：Dupilumab 是第一个可用于治疗特应性皮炎 (AD) 的生物制剂。其有效性和安全性已在临床试验中得到证实。 目的：我们试图在现实生活中的法国多中心回顾性队列中评估 dupilumab 对成人 AD 的有效性和安全性。方法：我们纳入了 2017 年 3 月至 2018 年 4 月期间接受治疗的患者。疗效结果，包括特应性皮炎评分 (SCORAD) 和湿疹面积和严重程度指数 (EASI) 评分，在基线和 3 个月时收集。随访时记录不良事件 (AE)。结果：我们纳入了 241 名患者。中位 6 四分位距 (IQR) 随访时间为 3.8 +/- 3.7 个月。 163 名患者中有 27 名 (16.6%) 的 SCORAD 改善≥ 75%，82 名患者中有 40 名 (48.8%) 的 EASI 改善≥ 75%。 3个月时的中位SCORAD和EASI评分显着低于基线（SCORAD +/- IQR，25 +/- 21 vs 56 +/- 27.4，P < 10(-9)，EASI +/- IQR，4.1 +/- 6.8 vs 17.9 +/- 15.4，P < 10(-9)）。 241 名患者中有 84 名 (38.2%) 报告有结膜炎。嗜酸性粒细胞增多的比例（
Background: Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.Objective: We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort.Methods: We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up.Results: We included 241 patients. The median 6 interquartile range (IQR) follow-up time was 3.8 +/- 3.7 months. A >= 75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a >= 75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD +/- IQR, 25 +/- 21 vs 56 +/- 27.4, P < 10(-9) and EASI +/- IQR, 4.1 +/- 6.8 vs 17.9 +/- 15.4, P < 10(-9), respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (